ZYDUSLIFEPharmaceuticals
Zydus Lifesciences Ltd — Profit & Loss Statement
₹871.20
+0.00%
Zydus Lifesciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -49.62 Cr | 21.57 Cr | -113.03 Cr | 47.42 Cr | — |
| Tax Rate For Calcs | 0.23 | 0.20 | 0.23 | 0.18 | — |
| Normalized EBITDA | 7.11K Cr | 5.51K Cr | 3.34K Cr | 3.43K Cr | — |
| Total Unusual Items | -76.80 Cr | 106.10 Cr | 96.10 Cr | 263.00 Cr | — |
| Total Unusual Items Excluding Goodwill | -211.80 Cr | 106.10 Cr | -498.00 Cr | 263.00 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 4.53K Cr | 3.84K Cr | 1.96K Cr | 2.24K Cr | — |
| Reconciled Depreciation | 915.80 Cr | 764.10 Cr | 722.70 Cr | 736.10 Cr | — |
| Reconciled Cost Of Revenue | 6.67K Cr | 6.50K Cr | 6.56K Cr | 5.82K Cr | — |
| EBITDA | 7.04K Cr | 5.62K Cr | 3.44K Cr | 3.69K Cr | — |
| EBIT | 6.12K Cr | 4.85K Cr | 2.72K Cr | 2.95K Cr | — |
| Net Interest Income | 85.90 Cr | 77.60 Cr | -54.10 Cr | -51.10 Cr | — |
| Interest Expense | 93.50 Cr | 44.00 Cr | 125.50 Cr | 114.40 Cr | — |
| Interest Income | 185.20 Cr | 126.80 Cr | 75.70 Cr | 68.80 Cr | — |
| Normalized Income | 4.82K Cr | 3.75K Cr | 2.94K Cr | 2.03K Cr | — |
| Net Income From Continuing And Discontinued Operation | 4.53K Cr | 3.86K Cr | 1.96K Cr | 4.49K Cr | — |
| Total Expenses | 16.59K Cr | 14.48K Cr | 14.03K Cr | 12.35K Cr | — |
| Rent Expense Supplemental | 30.60 Cr | 26.10 Cr | 22.90 Cr | 20.60 Cr | — |
| Diluted Average Shares | 100.62 Cr | 101.19 Cr | 101.56 Cr | 102.37 Cr | — |
| Basic Average Shares | 100.62 Cr | 101.19 Cr | 101.56 Cr | 102.37 Cr | — |
| Diluted EPS | 44.97 | 38.14 | 19.30 | 43.83 | — |
| Basic EPS | 44.97 | 38.14 | 19.30 | 43.83 | — |
| Diluted NI Availto Com Stockholders | 4.53K Cr | 3.86K Cr | 1.96K Cr | 4.49K Cr | — |
| Net Income Common Stockholders | 4.53K Cr | 3.86K Cr | 1.96K Cr | 4.49K Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 4.53K Cr | 3.86K Cr | 1.96K Cr | 4.49K Cr | — |
| Minority Interests | -147.10 Cr | -113.30 Cr | -131.60 Cr | -131.00 Cr | — |
| Net Income Including Noncontrolling Interests | 4.67K Cr | 3.97K Cr | 2.09K Cr | 4.62K Cr | — |
| Net Income Discontinuous Operations | 0.00 | 23.00 Cr | -4.60 Cr | 2.25K Cr | — |
| Net Income Continuous Operations | 4.67K Cr | 3.95K Cr | 2.10K Cr | 2.37K Cr | — |
| Tax Provision | 1.41K Cr | 977.50 Cr | 587.80 Cr | 511.70 Cr | — |
| Pretax Income | 6.03K Cr | 4.81K Cr | 2.59K Cr | 2.84K Cr | — |
| Other Non Operating Income Expenses | 8.90 Cr | 4.10 Cr | 3.60 Cr | 3.10 Cr | — |
| Special Income Charges | -251.70 Cr | -32.40 Cr | -583.40 Cr | 111.00 Cr | — |
| Other Special Charges | -34.50 Cr | 0.80 Cr | -10.70 Cr | -111.00 Cr | — |
| Write Off | 15.00 Cr | 0.30 Cr | 2.10 Cr | 2.60 Cr | — |
| Impairment Of Capital Assets | 84.60 Cr | 0.00 | — | 0.00 | 73.10 Cr |
| Restructuring And Mergern Acquisition | 66.60 Cr | 31.60 Cr | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | 85.90 Cr | 77.60 Cr | -54.10 Cr | -51.10 Cr | — |
| Total Other Finance Cost | 5.80 Cr | 5.20 Cr | 4.30 Cr | 5.50 Cr | — |
| Interest Expense Non Operating | 93.50 Cr | 44.00 Cr | 125.50 Cr | 114.40 Cr | — |
| Interest Income Non Operating | 185.20 Cr | 126.80 Cr | 75.70 Cr | 68.80 Cr | — |
| Operating Income | 5.98K Cr | 4.54K Cr | 2.85K Cr | 2.47K Cr | — |
| Operating Expense | 9.93K Cr | 7.98K Cr | 7.47K Cr | 6.53K Cr | — |
| Other Operating Expenses | 2.75K Cr | 2.24K Cr | 2.03K Cr | 1.73K Cr | — |
| Depreciation And Amortization In Income Statement | 915.80 Cr | 764.10 Cr | 722.70 Cr | 713.00 Cr | — |
| Amortization | 226.10 Cr | 129.20 Cr | 107.10 Cr | 145.20 Cr | — |
| Depreciation Income Statement | 689.70 Cr | 634.90 Cr | 615.60 Cr | 567.80 Cr | — |
| Research And Development | 189.40 Cr | 155.80 Cr | 135.80 Cr | 114.60 Cr | — |
| Selling General And Administration | 3.02K Cr | 2.18K Cr | 2.14K Cr | 1.80K Cr | — |
| Selling And Marketing Expense | 2.21K Cr | 1.66K Cr | 1.56K Cr | 1.37K Cr | — |
| General And Administrative Expense | 813.50 Cr | 517.60 Cr | 582.90 Cr | 428.10 Cr | — |
| Rent And Landing Fees | 30.60 Cr | 26.10 Cr | 22.90 Cr | 20.60 Cr | — |
| Gross Profit | 15.91K Cr | 12.52K Cr | 10.32K Cr | 9.01K Cr | — |
| Cost Of Revenue | 6.67K Cr | 6.50K Cr | 6.56K Cr | 5.82K Cr | — |
| Total Revenue | 22.57K Cr | 19.02K Cr | 16.88K Cr | 14.83K Cr | — |
| Operating Revenue | 22.57K Cr | 19.02K Cr | 16.88K Cr | 14.83K Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Zydus Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.